12012 — MIMEDI (Q190706): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Created claim: summary (P836): Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get invo...)
Property / financed by
 
Property / financed by: European Union / rank
Normal rank
 

Revision as of 06:32, 26 February 2020

Project in France financed by DG Regio
Language Label Description Also known as
English
12012 — MIMEDI
Project in France financed by DG Regio

    Statements

    0 references
    10,211,026.83 Euro
    0 references
    13,614,711.32 Euro
    0 references
    1 December 2017
    0 references
    30 November 2021
    0 references
    Université de Franche-Comté
    0 references

    47°14'23.03"N, 6°0'44.14"E
    0 references
    25030
    0 references
    Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
    0 references
    Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get involved, Migradi brings together research and industrial research laboratories from both the engineering and the cellular engineering sciences. (English)
    0 references

    Identifiers

    10341
    0 references